Dr. Gustavo Abel Espino, MD

Dr. Espino practices at U.S. Renal Care Albuquerque Home Dialysis in Albuquerque, New Mexico.

Dr. Espino's NPI, 1518985191, was assigned on July 18, 2006. Dr. Espino graduated from Universidad de Panama Faculty of Medicine in 1986. Dr. Espino holds New Mexico license 98-49.

Dr. Espino's primary practice is U.S. Renal Care Albuquerque Home Dialysis, at 4343 Pan American NE Fwy, Albuquerque, NM 87107 in Bernalillo County. The practice phone is (505) 355-1991.

Dr. Espino's primary practice is U.S. Renal Care Albuquerque Home Dialysis in Albuquerque, New Mexico. Dr. Espino is also affiliated with Presbyterian Hospital. The medical group on file is Albuquerque Nephrology Associates. Dmand AI also links Dr. Espino to 1 more hospital, 5 dialysis centers and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Espino practices, 8 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Espino's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Espino is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Espino's licenses on file in 4 states: New Mexico, Florida, Minnesota and Georgia.

Dmand AI lists chronic kidney disease, fluid and electrolyte imbalances, gout, hypercalcemia, kidney cysts and parathyroid gland disorder among the conditions Dr. Espino treats.

CMS data shows 748 Medicare services from Dr. Espino across 12 procedure codes in 2024, for 238 Medicare patients. Medicare paid $87,169 for them.

CMS counts 238 Medicare patients who saw Dr. Espino in 2024. The largest group is 75 to 84, with 89 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 18% are also on Medicaid. Their average risk score is 2.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Espino's median patient age at 70, with 52% women.

In 2024, Dr. Espino wrote 1,249 Medicare Part D claims for 213 patients. 87% of them were for generic drugs. CMS names the drug for 905 of them, across 25 drugs with 11 or more claims each, at $96,469 in total drug cost. In 2023, CMS named 1,171 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Espino for performance year 2024, reported as part of a group. Dr. Espino accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 12 papers to Dr. Espino, published from 2009 to 2024. 2018 was the busiest year, with 3. The most frequent topics are Antineoplastic Agents, Coated Materials, Biocompatible and Lower Urinary Tract Symptoms. Dr. Espino has published most often in Can Urol Assoc J. Dr. Espino's most frequent co-authors are Steven Abraham Kaplan, MD, Jessica M. Delong, MD and Rachel Ann Mann, MD.

Dmand AI links Dr. Espino to 1 clinical trial. Conditions studied include Prostatic Hyperplasia and Prostatic Diseases.

CMS Open Payments shows 213 general payments to Dr. Espino from 35 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Bayer HealthCare Pharmaceuticals Inc. paid the most, $626.

Dr. Espino graduated from Universidad de Panama Faculty of Medicine in 1986. Dr. Espino is a member of ACP.

Dr. Espino is in network with 15 carriers, including Aetna, United Healthcare and Cigna. HMO plans come from the most carriers, 9. Check the plan with the practice before a visit.